EXCLUSIVE: NewcelX Submits Pre-IND Briefing Package To FDA for Type 1 Diabetes Therapy NCEL-101; Schedules Type B Pre-IND Meeting With FDA For Late June (

Benzinga Newsdesk www.benzinga.com Neutral 86.5%

Neg 0% Neu 86.5% Pos 0%

Comments

No comments yet. Be the first!